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Infant CD4+ T-cell responses to bacterial infections or vaccines have been extensively studied, whereas studies on CD8+ T-cell
responsesfocusedmainlyonviralandintracellularparasiteinfections.HereweinvestigatedCD8+ T-cellresponsesuponBordetella
pertussis infection in infants, children, and adults and pertussis vaccination in infants. Filamentous hemagglutinin-speciﬁc IFN-
γ secretion by circulating lymphocytes was blocked by anti-MHC-I or -MHC-II antibodies, suggesting that CD4+ and CD8+
T lymphocytes are involved in IFN-γ production. Flow cytometry analyses conﬁrmed that both cell types synthesized antigen-
speciﬁc IFN-γ, although CD4+ lymphocytes were the major source of this cytokine. IFN-γ synthesis by CD8+ cells was CD4+ Tc e l l
dependent, as evidenced by selective depletion experiments. Furthermore, IFN-γ synthesis by CD4+ cells was sometimes inhibited
by CD8+ lymphocytes, suggesting the presence of CD8+ regulatory T cells. The role of this dual IFN-γ secretion by CD4+ and
CD8+ T lymphocytes in pertussis remains to be investigated.
1.Introduction
The immune system of neonates and young infants diﬀers in
manyaspectsfromthatofadults,whichhasimportantimpli-
cations for the development of eﬀective and safe immune-
interventions and vaccination in early life. Compared to that
of adults, the neonatal adaptive immune system is immature
with respect to both B- and T-cell responses [1–4], the latter
being partially impaired as a result of a functional alteration
of neonatal antigen presenting cells (APCs) [5]. Whereas
several vaccines administrated during infancy require the
development of antigen-speciﬁc IFN-γ responses to be pro-
tective, the CD4+ T-cell responses in newborns and infants
appear to be most often biased towards the Th-2 type. Upon
stimulation with the vaccine antigens, the CD4+ T-cell re-
sponses are often characterized by the production of IL-4,
IL-5, and IL-13 at the expense of IFN-γ [6, 7].
However, in certain circumstances, even very young in-
fants are able to mount a robust Th-1 type response, with
high levels of IFN-γ secretion, and minimal amountsof Th-2
cytokine production. It has been demonstrated that vac-
cination at birth with Mycobacterium bovis Bacille Calmette-
Gu´ erin (BCG) induces INF-γ responses to puriﬁed protein
derivative at levels similar to those induced by BCG vacci-
nation in older children and in adults [8]. Natural infection
with the whooping cough agent Bordetella pertussis also2 Clinical and Developmental Immunology
induces strong B. pertussis-antigen-speciﬁc IFN-γ responses
in very young infants, with no detectable IL-13 or IL-4 pro-
duction [9].
Studies on antigen-speciﬁc IFN-γ responses in infants
have so far mostly focused on CD4+ T cells, and much less
is known about the capacity of infants to induce CD8+-
IFN-γ-producing cells. Compared to adults, infants have sig-
nificantly reduced CD8+ T-lymphocyte proportions in their
peripheral blood mononuclear cell (PBMC) population [3,
10]. Nevertheless, strong CD8+ T-cell responses have been
detected in infants congenitally infected with cytomegalovi-
rus[11]orTrypanosomacruzi[12].However,bothinfectious
agents are primarily or exclusively intracellular pathogens,
which is likely one of the reasons for their ability to induce
strong CD8+ T-cell responses. Virtually nothing is known
about the potential of extracellular pathogens or protein vac-
cines to induce CD8+ T-cell responses in infants or early
childhood.
In this study, we used pertussis vaccination and disease
to address this issue. Despite wide vaccination coverage with
eﬃcacious vaccines, pertussis or whooping cough cases still
mount to up to 50 million per year, with nearly 300,000 an-
nual deaths recorded worldwide [13]. We and others have
previouslyreportedastrongproductionofIFN-γ inresponse
to in vitro stimulation with B. pertussis antigens, such as
ﬁlamentous hemagglutinin (FHA) of PBMC from children
presenting with whooping cough [9, 14–16] or vaccinated
with pertussis vaccines [17–20], including preterm infants
with very low gestational age [21]. Here, we have character-
ized the phenotype of the IFN-γ-producing lymphocytes in
response to FHA in a cohort of acutely B. pertussis-infected
infants and young adults, as well as in pertussis-vaccinated
children, to determine whether CD8+ lymphocytes may play
a signiﬁcant role in B. pertussis-speciﬁc IFN-γ responses in
infants, compared to older children and adults.
2.MaterialandMethods
2.1. Study Participants and Blood Collection. A total of 31 B.
pertussis-infected subjects and 27 vaccinated children were
enrolled in the study. Among the infected subjects, 25 were
infants younger than 1 year of age (median, range in months:
2, 0–7), and 6 were adolescents or young adults (median,
range in years: 12.5, 11–32). All cases were conﬁrmed by
polymerase-chain reaction (PCR) and/or B. pertussis culture,
andbloodwascollectedduringtheacutephaseofthedisease.
Amongthe27vaccinatedchildren,4hadreceivedthecellular
vaccine Tetracoq (sanoﬁ pasteur, Lyon, France), 17 had re-
ceived the acellular vaccine Tetravac (sanoﬁ pasteur, France),
and 6 had received the acellular vaccine Infanrix hexa (GSK
Biologicals, Rixensart, Belgium). Some of the vaccinated
children had already been included in the analysis of other
parametersoftheimmuneresponsetopertussisvaccines[22,
23]. All infants followed the vaccination schedule according
to the Belgian recommendation, and blood samples were
collectedatamedianageof11months(range:3–18months).
Therefore, most of them had received at least 3 vaccine injec-
tions,excepttwoinfantstestedafteronly2vaccineinjections,
and two others tested after having received the ﬁrst booster
dose. All vaccinated children were HIV-negative but were in
utero HIV-exposed and therefore received a preventive ther-
apy with zidovudine during the ﬁrst 6 weeks of life.
This study was approved by the ethical committees from
the Hˆ opital Saint-Pierre (Brussels, Belgium) and the Hˆ opital
Erasme (Brussels, Belgium), and informed parental consent
was obtained. Due to the small volume of blood, not all anal-
yses could be performed for all the subjects.
2.2. Antigens, Mitogen, and Blocking Antibodies for Cellu-
lar Immune Assays. FHA was puriﬁed by heparin-Sepharose
chromatography as described [24] from pertussis toxin-
deﬁcient B. pertussis BPRA [25], and its concentration was
estimated by BCA Protein Assay Reagent Kit (Pierce Biotech-
nology, Rockford, USA). FHA was used at 1 or 5μg/mL, as
speciﬁed for the in vitro stimulation. Phytohemagglutinin
(PHA) (Remel, Lenexa, KS, USA) was used as a positive con-
trol at 2μg/mL.
When indicated, blocking anti-human MHC-I or -II
antibodies (mouse anti-human HLA-ABC antigen, clone
W6/32 or mouse anti-human HLA-DP, DQ, DR antigen,
clone CR3/43, respectively, DAKO Diagnostics S.A., Hever-
lee, Belgium) or the corresponding isotype control antibod-
ies (mouse IgG1 or IgG2a, DAKO Diagnostic S.A., Belgium)
were added in the culture medium at 2μg/mL.
2.3. Cell Isolation and Culture: Cytokine Concentration Deter-
mination. Blood samples were processed within 4h follow-
ing the puncture. PBMC were isolated from whole blood by
density gradient centrifugation on lymphoprep (Nycomed
Pharma, Oslo, Norway) and cultured at 2 × 106/mL with the
stimulating antigen/mitogen in supplemented RPMI medi-
umat37◦Cunder5%CO2,aspreviouslydescribed[9].After
72h, supernatants were collected, and IFN-γ production was
measured using sandwich enzyme-linked immunosorbent
assays (ELISAs), according to the manufacturers’ instruc-
t i o n s( K i tI F N - γ cytoset ELISA, BioSource International,
Camarillo, CA, USA). IFN-γ concentrations were calculated
using the KC4 software (BRS, Drogenbos, Belgium) by re-
ferring to a standard curve generated by serial dilutions of
the standard, from 2,500pg/mL to 10pg/mL IFN-γ. When
detectable, IFN-γ concentrations obtained under nonstim-
ulated conditions were subtracted from those obtained for
mitogen- or antigen-stimulated cells.
2.4. Lymphocyte Depletions. CD4+ or CD8+ Tl y m p h o c y t e s
were depleted by incubating whole blood with anti-CD4 or
anti-CD8 antibodies for 20 minutes at room temperature
(RosetteSep, StemCell Technologies, Grenoble, France), fol-
lowed by a density gradient centrifugation on lymphoprep
(Nycomed Pharma, Norway). The eﬀectiveness of the de-
pletion was controlled by ﬂow cytometry (FACSCalibur or
FACSCanto, BD Biosciences, Mountain view, CA, USA) after
staining the cells with a combination of anti-human mon-
oclonal antibodies (anti-CD3-PerCp-Cy5.5, anti-CD4-APC,
anti-CD8-FITC, anti-CD14-PE, BD Biosciences, USA). Per-
centages of remaining CD4+ T cells in the CD4+-depleted
cell suspensions were always lower than 3% of the total
T lymphocytes, and percentages of the remaining CD8+Clinical and Developmental Immunology 3
lymphocytes were always lower than 0.7% in the CD8+-
depleted cell suspensions. The median of CD14+ percentages
after CD4+ T-cell depletion was 10.3% (range = 5.3–28%) of
the whole PBMC. The analyses were performed using cell-
quest (BD Biosciences, USA) or FlowJo (Tree Star, Ashland,
OR, USA).
2.5. Phenotyping of FHA-Speciﬁc IFN-γ-Containing Cells.
Isolated PBMC were stimulated overnight with 5μg/mL of
FHA in the presence of 2μg/mL of each of the costimulatory
antibodies α-CD28 (clone L293, BD Biosciences, USA) and
α-CD49d (clone L25.3, BD Biosciences, USA). 10μg/mL
Brefeldin-A (Sigma Aldrich, Saint Louis, MO, USA) was
added for the last 4h of incubation. After ﬁxation and per-
meabilization of the cells according to the manufacturers’ in-
structions (Lysing-Solution1 and Permeabilizing-Solution2,
BD Biosciences, USA), PBMC were stained with anti-human
monoclonal antibodies: anti-CD3-PerCp-Cy5.5, anti-CD4-
APC-Cy7, anti-CD8-APC, and anti-IFN-γ-PE (BD Bioscien-
ces, USA). Stained cells were examined using a FACSCanto
ﬂowcytometer(BDBiosciences,USA),andthedatawerean-
alyzed by using the FlowJo software (Tree Star, USA). When
detectable, percentages of IFN-γ-containing CD4+ or CD8+
CD3+ T lymphocytes obtained under nonstimulated condi-
tions (median = 0.1%) were subtracted from those obtained
for FHA-stimulated cells. Both percentages and absolute
numbers of CD4+-o rC D 8 +-containing IFN-γ were evaluat-
ed. Absolute numbers of positive cells reported for 1,000,000
CD3+ T cells were calculated as follows:

% FHA-induced IFN-γ producing CD4+ or CD8+ cells

×(%C D 4 + or CD8+ cells within CD3+ Tc e l l s )
×
106
100
.
(1)
2.6. Statistical Analysis. The statistical analyses were per-
formed using the GraphPad Prism version 4.00 for Win-
dows (GraphPad Software, San Diego, CA, USA, http://www
.graphpad.com/). The signiﬁcance of diﬀerences between
diﬀerent series of results was determined using nonparamet-
ric Wilcoxon matched pairs test.
3. Results
3.1.EﬀectofBlockingAnti-MHCClass-IandClass-IIAntibod-
ies on the IFN-γ Production Induced by FHA. As a ﬁrst ap-
proach to analyse the possible contribution of CD4+ and/or
CD8+ TlymphocytesintheFHA-inducedIFN-γ production,
we analysed the MHC restriction of this IFN-γ secretion by
testingtheeﬀectofblockingantibodiesagainsttheclassIand
classIIMHCmolecules.TheFHA-inducedIFN-γ concentra-
tions obtained in the presence of these blocking antibodies
were compared to those obtained in the presence of isotype
controls (Figure 1). Compared to the addition of an isotype
control to the FHA-stimulated PBMC, the addition of an
anti-MHC-II antibody inhibited the IFN-γ secretion for
both B. pertussis-infected subjects (P = 0.0186, Figure 1(a))
and vaccinated children (P = 0.0005, Figure 1(b)). A total
inhibition of the FHA-induced IFN-γ secretion in the pres-
ence of anti-MHC-II antibodies was noted for 8/15 infected
patients and for 5/12 vaccinated children. In contrast, no
inhibition was observed for 3 infected children but their
FHA-induced IFN-γ secretion was inhibited by the addition
of an anti-MHC-I antibody suggesting that in these cases,
CD8+ lymphocytes were the predominant IFN-γ producing
lymphocyte subset. The results obtained in the presence of
anti-MHC-II antibodies were similar for infected infants,
children, and adults as well as for children vaccinated with
an acellular vaccine and with a whole cell vaccine (data not
shown).
Anti-MHC-I antibodies also inhibited the FHA-induced
IFN-γ secretion compared to the addition of an isotype con-
trol, both in infected children (P = 0.0079, Figure 1(c))a n d
in vaccinated children (P = 0.0034, Figure 1(d)). The inhi-
bition was total for some children and partial for others with
nodiﬀerenceaccordingtothechildren’sage.Interestingly,for
6 children (5 infected and 1 vaccinated), the FHA-induced
IFN-γ concentrations were noticeably higher in the presence
of an anti-MHC-I antibody than in the presence of the iso-
type control (Figures 1(c) and 1(d)).
These results indicate that both the MHC class-I and
MHC class-II molecules are involved in the recognition of
FHA, and that they are both required for the optimal secre-
tionofIFN-γ byPBMCinresponsetostimulationwithFHA.
This suggests the involvement of both CD8+ and CD4+ lym-
phocytes in the FHA-induced IFN-γ secretion.
3.2. Phenotyping of FHA-Speciﬁc IFN-γ-Producing Cells. To
conﬁrm that both CD4+ and CD8+ lymphocytes participate
in the IFN-γ synthesis induced by FHA, the phenotype of the
cells was analysed by ﬂow cytometry after simultaneous im-
munostaining of intracellular IFN-γ and surface markers on
FHA-stimulated cells for 10 children (6 infected and 4 vacci-
nated).
The percentages and absolute numbers of CD4+ and
CD8+-IFN-γ containing lymphocytes obtained in response
to a stimulation with FHA and after subtraction of the values
obtained for nonstimulated cells are represented on Figure 2.
Whereas IFN-γ-containingCD4+ lymphocytesweredetected
for all the subjects (median and 25th–75th percentiles of
the IFN-γ-containing-CD3+CD4+ cells: 0.06% and 0.01–
0.21%, resp.), IFN-γ-containing CD8+ lymphocytes were
o n l yd e t e c t e df o r6 / 1 0c h i l d r e n( 3 / 6i n f e c t e da n d3 / 4v a c -
cinated) (median and 25th–75th percentiles of the IFN-γ-
containing-CD3+CD8+ cells: 0.04% and 0.00–0.11%, resp.),
resulting therefore in a signiﬁcantly lower percentage of IFN-
γ-containing CD8+ compared to CD4+ lymphocytes (P =
0.0164) (Figure 2(a)).
As the numbers of circulating CD4+ lymphocytes are
normally higher than the numbers of CD8+ lymphocytes,
even more signiﬁcant diﬀerences between the contribu-
tions of CD4+ and CD8+ lymphocytes to the FHA-induced
IFN-γ synthesis were noted when comparing the abso-
lute numbers of IFN-γ-containing-T lymphocytes (P =
0.0020, Figure 2(b)). Although it has not been possible to
analyze the amounts of IFN-γ produced by individual cells,4 Clinical and Developmental Immunology
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Figure 1: Eﬀect of blocking anti-MHC class I and anti-MHC class II antibodies on the FHA-speciﬁc IFN-γ production. Isolated PBMC
were stimulated in vitro for 72h with 1μg/mL FHA in the presence or absence of blocking anti-MHC-II (a) and (b) or anti-MHC-I (c)
and (d) antibodies or in the presence or absence of control isotypes. Unstimulated cells were tested as control. IFN-γ concentrations were
measured in the cell culture supernatants and values obtained for unstimulated cells were subtracted from those obtained for stimulated
cells. Circles represent the individual IFN-γ concentrations obtained after stimulation with FHA in the presence of anti-MHC antibodies or
control isotypes. Results obtained for the same samples are linked. ∗P<0.05; ∗∗P<0.001; ∗∗∗P<0.0001.
taken together with the data shown in Figure 1, these results
indicate that the CD4+ T cells are the major source of FHA-
speciﬁc IFN-γ, yet for some children the CD8+ cells con-
tribute signiﬁcantly to the IFN-γ production. A represent-
ativedotplotoftheunstimulatedversusFHA-inducedIFN-γ
synthesis in CD4+ and CD8+ lymphocytes is shown on
Figure 3.
3.3. CD4+-CD8+ T-Lymphocyte Interactions in the FHA-In-
duced IFN-γ Secretion. The CD4+ T cells or the CD8+ Tc e l l s
were depleted from the PBMC of 5 infected infants before
in vitro stimulation with FHA. We also depleted the CD4+
T cells from 11 vaccinated children, and the CD8+ Tc e l l s
from 3 of them before in vitro stimulation with FHA. The
PBMC and the CD4+-depleted and the CD8+-depleted cell
suspensions were then cultured in the presence or absence
of FHA for 72h, and the IFN-γ concentrations present
in the cell culture supernatants were measured by ELISA.
The eﬀect of the depletions was assessed by comparing the
IFN-γ concentrations in the depleted cell culture to thoseClinical and Developmental Immunology 5
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Figure 2: Percentages and absolute numbers of FHA-induced IFN-γ producing CD4+ and CD8+ Tc e l l si nB. pertussis-infected (n = 6)
or vaccinated children (n = 4). Isolated PBMC were stimulated in vitro for 24h with 5μg/mL FHA, and IFN-γ-containing CD4+ (left
columns) and CD8+ (right columns) T lymphocytes were detected by ﬂow cytometry. (a) represents the percentages of positive cells and
the absolute numbers of IFN-γ-producing cells expressed for 106 CD3+ T lymphocytes are shown on (b). The lines join the results obtained
for the same children. Percentages obtained for unstimulated cells were subtracted from those obtained for stimulated cells. ∗P<0.05,
∗∗P<0.001.
of the whole PBMC supernatants. As shown in Figure 4,
depletion of the CD4+ T cells resulted in a total loss of the
FHA-speciﬁc IFN-γ production for all but one child (n◦2),
suggestingthattheIFN-γ secretionbyCD8+ lymphocytesre-
quires the help from CD4+ lymphocytes. The FHA-induced
IFN-γ concentrations were therefore signiﬁcantly lower for
the CD4+-depleted cell suspensions compared to the PBMC
(P = 0.0005). The residual FHA-induced IFN-γ secretion by
the CD4+-depleted cell suspension for one subject (n◦2, 12-
year-old-infectedchild)couldperhapsbeattributedtoIFN-γ
secretion by double negative cells, such as NK cells or by γδ
T lymphocytes, that were still present in the CD4+-depleted
cell suspension. However, due to limited amounts of cells
available, this could not be further investigated.
In contrast, results obtained after the depletion of the
CD8+ T cells were highly variable with an absence of residual
IFN-γ secretion for 2/8 subjects (1 infected and 1 vaccinat-
ed), lower but detectable levels of IFN-γ secretion compared
to the PBMC for 3/8, and higher IFN-γ secretion compared
t oP B M Cf o r3 / 8s u b j e c t s( 2i n f e c t e ds u b j e c t so f3m o n t h s
and 12 years of age and one 14-month-old-vaccinated child).
These results are consistent with those obtained by the
additionofblockinganti-MHCclassIantibodiesandsuggest
that FHA-induced CD8+ lymphocytes can sometimes inhibit
the FHA-induced CD4+ T-cell-mediated IFN-γ synthesis,
whereas in other circumstances, CD8+ lymphocytes repre-
sent a signiﬁcant source of IFN-γ.
4. Discussion
The comprehensive knowledge of the immune responses
elicited by infectious agents that induce long-term protective
immunity in infected patients may be instrumental for the
design of optimal vaccine strategies against these microbes.
Whereas most work on the adaptive cellular immune re-
sponses to extracellular pathogens has so far focused on the
CD4+ T-cell responses, little is known on the possible induc-
tion of speciﬁc CD8+ T-cell responses. The susceptibility of
infants to several severe infections with extracellular bacteria
is partially attributed to a delayed maturation of their CD4+
T-cellresponseswithadelayintheIFN-γ secretion[4].How-
ever, in addition to antigen-speciﬁc CD8+ T-cell responses in
CMV- and Trypanosoma cruzi-infected infants [11, 12], the
data reported hereindicate thatB.pertussisinfection alsocan
result in CD8+ T-cell-mediated IFN-γ responses, in addition
to CD4+ responses. As IFN-γ is one of the factors that play
a role in protection against B. pertussis infection [26], these
data provide new insights in the mechanisms of protective
immunity against B. pertussis, a major pathogen in view of
the high prevalence of whooping cough worldwide in spite
of extensive use of eﬃcacious vaccines. The incidence of
whoopingcoughisactuallyrisingincountrieswithhighvac-
cinecoveragewitha5-foldincreaseinthenumberofwhoop-
ing cough cases reported in June 2010 in California, com-
pared to the same time period in 2009 [27].6 Clinical and Developmental Immunology
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Figure 3: Dot-plot of the ﬂow cytometric analyses of the phenotype of FHA-induced IFN-γ producing cells for one representative subject.
Isolated PBMC were cultured in vitro for 24h in the presence (lower panels) or absence (upper panels) of FHA. CD4+ T cells (left panels) or
CD8+ T cells (right panels) were gated in the CD3+ T lymphocytes. Results are expressed as the percentages of IFN-γ producing cells among
the cell subpopulation analyzed.
T h ed u a lr o l e so fC D 4 + and CD8+ lymphocytes in the
FHA-induced IFN-γ production were determined by the use
ofblockinganti-MHCclassIoranti-MHCclassIIantibodies
and by ﬂow cytometry. This is in contrast to the classical
concept that after phagocytosis of bacteria, their antigens are
presented to CD4+ T lymphocytes by an MHC-class II-de-
pendent pathway. Exceptions to this rule have been reported
for intracellular bacteria, such as mycobacteria, which were
shown to also induce CD8+ responses [28–30]. However, to
our knowledge, the involvement of CD8+ T cells in the cel-
lular immune responses to extracellular bacteria, such as B.
pertussis, has not been addressed in details previously.
It has been shown that FHA can bind to CR3, which may
result in uptake of the bacteria in CR3-expressing cells [31–
33] and inhibition of the phagosome-lysosome fusion [31,
34]. FHA may then be presented by MHC class I via a cross-
presentation pathway, as already demonstrated for intracel-
lular bacteria [35, 36]. Alternatively, as FHA was shown to
strongly bind to adenylate cyclase toxin (CyaA) [37], we can
therefore not formally exclude a slight contamination of the
FHA preparation by CyaA. This protein may then serve as
a vector for cytosolic delivery of FHA, thereby allowing its
presentation to CD8+ lymphocytes through the MHC class
Im o l e c u l e s[ 38, 39]. CyaA has previously been shown to be
directly delivered into the cytosolic pathway for MHC class
I-restricted antigen presentation [40].
Even though both CD4+ and CD8+ lymphocyte subsets
participate in the FHA-speciﬁc IFN-γ production, the major
source of FHA-speciﬁc IFN-γ is the CD4+ T-lymphocyte
subset in most of the infected or vaccinated children. Inter-
estingly however, the CD4+ T-cell-mediated IFN-γ secretion
appears to be modulated at least in some children by CD8+
lymphocytes,asshownbytheenhancedFHA-inducedIFN-γ
concentrations measured in the cell culture supernatantsClinical and Developmental Immunology 7
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Figure 4: Eﬀe c to ft h eC D 4 + or CD8+ depletion on the FHA-
induced IFN-γ production by PBMC from B. pertussis-infected or
vaccinatedchildren.IsolatedPBMCwerestimulatedinvitrofor72h
with 1μg/mL FHA after CD4+ (a) or CD8+ (b) depletion. Results
from infected children are represented by columns 1 to 5 whereas
those from vaccinated children are indicated by numbers 6 to 16.
Open columns represent the values obtained for the nondepleted
cell suspension and grey columns those obtained after CD4+ or
CD8+ depletions. The arrows indicate the samples characterized by
ahigherIFN-γ secretioninCD8-depletedcellsuspensioncompared
to the PBMC.
after CD8+ T-cell depletion or in the presence of block-
ing anti-MHC-I antibodies. CD8+ lymphocytes have been
reported in diﬀerent human infections to secrete inhibitory
cytokines, such as IL-10 or IL-4 [41–43], and CD8+CD25+
regulatory T cells have also been reported to suppress the
CD4+ T-cell-mediated IFN-γ production and proliferation
[44,45].Suchcellsmaybeinducedtoavoidexcessiveinﬂam-
matory responses during whooping cough or in response to
pertussis vaccines.
On the other hand, the FHA-induced IFN-γ synthesis
by CD8+ T lymphocytes was most often dependent on the
CD4+ lymphocytes, as shown by the sharp decrease in IFN-
γ secretion by CD8+ lymphocytes in the absence of CD4+
lymphocytes. The concept that helper CD4+ T cells may be
essential for CD8+ T-cell primary response was established
bydiﬀerentstudiesinrecentyears[46,47],andseveralmech-
anisms have beenproposed. Antigen-presenting cellsactivat-
ed by the CD4+ lymphocytes through CD40-CD40L interac-
tion may stimulate the response of CD8+ Tl ym p h o c yt e s .F o r
B. pertussis antigens, the antigen-presenting cells may be B
lymphocytes expressing CD40 that were suggested to be able
to present FHA to T lymphocytes [[23] and our unpublished
data]. Alternatively, CD8+ T cells may be primed by the re-
lease of cytokines, such as IFN-γ and IL-2 by the CD4+ T
lymphocytes, as was reported for the priming of cytotoxic
eﬀectors CD8+ cells [48].
The role of the FHA-induced CD8+ T-cell responses in
protection is not known. No protective role of CD8+ Tc e l l s
was demonstrated in B. pertussis-infected mice so far [49–
51]. However, whole cell pertussis vaccine has been used in
a mouse model as adjuvant to induce a cytotoxic activity
against a tumor peptide [52]. It is therefore possible that
the FHA-induced IFN-γ production by CD8+ lymphocytes
is accompanied by a cytotoxic function of these cells. On the
other hand, the CD8+ T-cell-mediated IFN-γ secretion may
reﬂect the adjuvant activity of B. pertussis, and the role of
B. pertussis-speciﬁc CD8+ lymphocytes may be diﬀerent in
humans and in mice. Whether a cytotoxic activity against
B. pertussis may be helpful for protection against B. pertussis
infection in humans or whether the antigen-speciﬁc CD8+ T
cells mostly play a role in the control of the CD4+ response
remains to be determined. However, the involvement of
both the CD4+ and the CD8+ lymphocytes in the IFN-γ
response induced by extracellular bacteria suggests a role
of a crosstalk between these lymphocyte subpopulations in
the regulation of the adaptive immune response to bac-
teria.
5. Conclusion
Although CD4+ T-cell responses to B. pertussis antigens
have been extensively studied, little is known about CD8+
T-cell responses to these antigens in B. pertussis-infected or
vaccinated children. In fact, CD8+ T-cell responses in bac-
terial infections or to nonlive vaccines have attracted lim-
ited attention so far, in contrast to viral or intracellular par-
asite infections. Here, we found that B. pertussis infection
of infants with a median age of 2 months or young adults
induces a strong IFN-γ response to FHA, a major B. pertussis
antigen, and that the FHA-speciﬁc IFN-γ response is me-
diated by both CD4+ T cells and CD8+ T cells. Although
the CD4+ T cells constitute the major source of FHA-spe-
cific IFN-γ, in some children substantial amounts of IFN-γ
were produced by the CD8+ T cells. This was determined
by the use of speciﬁc inhibitory anti-MHC class I and
MHC-class II antibodies, as well as by ﬂow cytometry, which
showed that the major FHA-speciﬁc IFN-γ-secreting cell
populations were the CD4+ T cells, both in infected and in
vaccinated children. Cell depletion experiments showed that
CD8+ T-cell-mediated IFN-γ secretion depends on the help
of CD4+ T cells. Interestingly, in some children, depletion
of the CD8+ T cells resulted in a substantial increase of
FHA-speciﬁc IFN-γ, suggesting that these CD8+ T-cells may
have immunoregulatory functions. Thus, a bacterial infec-
tion with B. pertussis or vaccination with nonlive vaccines,
such as the whole-cell or the acellular pertussis vaccines, may
induce a strong CD8+ T-cell response in children. The role of
this response in protection against pertussis awaits further
investigation.8 Clinical and Developmental Immunology
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